Thursday, July 27, 2017 7:19:01 PM
Gene-based immunotherapy targeting a range of cancers
Status: Pre–Clinical complete
Immunotherapy
OXB-302 is a gene-based cancer immunotherapy targeting a wide range of tumours and a number of haematological malignancies.
Our approach
OXB-302 is a novel oncology product that combines Oxford BioMedica’s lentiviral vector platform and 5T4 technology platforms. This cell therapy uses the LentiVector® platform to engineer patients’ harvested T-cells to express an antibody against the 5T4 antigen, which is expressed on the cell surface in many common cancers. These T-cells are then infused back into the patient, and subsequently recognise the 5T4 tumour antigen and initiate cell killing immune mechanisms.
Proof of concept
OXB-302 has completed pre-clinical development, delivering encouraging efficacy in an industry standard in vivo tumour challenge model.
Clinical status
Following the successful completion of preclinical development, planning for a Phase I/II clinical study is well underway, with a regulatory submission anticipated in the near future.
Market opportunity
The targeted cancer treatment and immunotherapy market is forecast to grow to $36.8 billion by 2019. With a large number of cancers expressing the 5T4 antigen, OXB-302 has significant market potential if successful in any of its target indications.
http://www.oxfordbiomedica.co.uk/pipeline
Good luck and GOD bless,
George
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM